24/7 Market News Snapshot 17 June, 2025 – Processa Pharmaceuticals, Inc. Common (NASDAQ:PCSA)

June 17, 2025

DENVER, Colo., 17 June, 2025 (www.247marketnews.com) – (NASDAQ:PCSA) are discussed in this article.
Processa Pharmaceuticals, Inc. has recently captured the market’s attention with a remarkable surge in its stock price, which has soared 203.86% to $0.684, up from a previous close of $0.225. This impressive rally is bolstered by an extraordinary trading volume of 51.33 million shares, indicating strong investor interest and potential for continued upward momentum. Analysts suggest that this breakout could present fruitful opportunities for investors in the expanding biotech sector, and many are closely monitoring the stock’s trajectory.

In tandem with this market excitement, Processa has announced a strategic partnership with Intact Therapeutics, a collaboration aimed at pioneering innovative therapies for gastrointestinal disorders. As part of a recently executed binding term sheet, Intact has obtained exclusive licensing options for Processa’s lead candidate, PCS12852, a novel 5-HT4 receptor agonist that shows promise as a treatment for gastroparesis and other gastrointestinal motility disorders.

This agreement is projected to generate significant financial benefits for Processa, including $2.5 million in upfront option exercise fees and the possibility of up to $20 million in development and regulatory milestone payments. Further, the company could earn more than $432.5 million in commercial milestones and an ongoing double-digit royalty on future global sales of the licensed product. Notably, Processa is also set to obtain an equity interest in Intact as this partnership progresses.

George Ng, CEO of Processa, emphasized the importance of this collaboration, stating, “We view this agreement as a key opportunity to unlock the value of our non-oncology assets while maintaining our dedication to developing next-generation cancer therapies.” Meanwhile, Intact Therapeutics holds a commitment to enhancing patient outcomes in gastrointestinal health, with CEO Ravi Pamnani expressing enthusiasm for utilizing PCS12852’s clinical data to strengthen their portfolio. This strategic partnership not only highlights the potential of PCS12852 but also reflects the relentless drive of both companies to advance patient care through groundbreaking innovations.

Related news for (PCSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.